Trinity Biotech plc (TRIB) P/E Ratio History
Deep ValueTrading at -0.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1999–2021
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Trinity Biotech plc (TRIB) trades at a price-to-earnings ratio of -0.2x, with a stock price of $0.36 and trailing twelve-month earnings per share of $-2.01.
The current P/E is 100% below its 5-year average of 890.9x. Over the past five years, TRIB's P/E has ranged from a low of 77.6x to a high of 5451.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, TRIB trades at a 101% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, TRIB trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TRIB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TRIB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TRIB P/E vs Peers
Point-of-Care and Rapid Testing peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 38.0 | 1.96Best | +31% | |
| $163B | 25.2 | 3.05 | -51% | |
| $8B | 10.8Lowest | - | +143%Best | |
| $17B | 30.5 | - | -25% | |
| $44B | 42.2 | 2.95 | +23% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TRIB Historical P/E Data (1999–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q4 | Dec 31 2021 | $35.75 | $0.26 | 136.5x | -70% |
| FY2016 Q2 | - | $283.50 | $0.05 | 5451.9x | +1101% |
| FY2016 Q1 | - | $291.50 | $0.07 | 4416.7x | +873% |
| FY2015 Q4 | - | $294.00 | $0.48 | 617.6x | +36% |
| FY2015 Q3 | Sep 30 2015 | $286.00 | $0.55 | 523.8x | +15% |
| FY2015 Q2 | - | $451.50 | $0.63 | 717.8x | +58% |
| FY2015 Q1 | - | $481.25 | $0.71 | 677.8x | +49% |
| FY2014 Q4 | Dec 31 2014 | $437.75 | $0.72 | 608.0x | +34% |
| FY2014 Q3 | - | $456.75 | $0.73 | 625.7x | +38% |
| FY2013 Q2 | Jun 30 2013 | $421.25 | $0.75 | 561.7x | +24% |
| FY2013 Q1 | Mar 31 2013 | $422.00 | $0.77 | 548.1x | +21% |
| FY2012 Q4 | Dec 31 2012 | $360.50 | $0.78 | 462.2x | +2% |
| FY2012 Q3 | Sep 30 2012 | $314.25 | $0.76 | 413.5x | -9% |
| FY2012 Q2 | Jun 30 2012 | $300.00 | $0.74 | 405.4x | -11% |
| FY2012 Q1 | Mar 31 2012 | $266.75 | $0.71 | 375.7x | -17% |
| FY2011 Q4 | Dec 31 2011 | $254.50 | $0.69 | 368.8x | -19% |
| FY2011 Q3 | Sep 30 2011 | $229.00 | $0.66 | 347.0x | -24% |
| FY2011 Q2 | - | $248.50 | $0.62 | 400.8x | -12% |
| FY2011 Q1 | - | $234.50 | $2.86 | 82.0x | -82% |
| FY2010 Q4 | Dec 31 2010 | $220.25 | $2.84 | 77.6x | -83% |
| FY2010 Q3 | - | $158.25 | $2.84 | 55.7x | -88% |
| FY2010 Q2 | Jun 30 2010 | $152.00 | $2.84 | 53.5x | -88% |
| FY2010 Q1 | Mar 31 2010 | $136.25 | $0.58 | 234.9x | -48% |
| FY2009 Q4 | - | $101.00 | $0.55 | 183.6x | -60% |
| FY2008 Q3 | - | $70.50 | $16.37 | 4.3x | -99% |
| FY2008 Q2 | Jun 30 2008 | $96.50 | $16.25 | 5.9x | -99% |
| FY2008 Q1 | Mar 31 2008 | $114.75 | $16.06 | 7.1x | -98% |
| FY2007 Q4 | Dec 31 2007 | $170.25 | $15.98 | 10.7x | -98% |
| FY2006 Q1 | Mar 31 2006 | $227.75 | $0.57 | 396.1x | -13% |
| FY2005 Q4 | Dec 31 2005 | $204.00 | $0.97 | 209.2x | -54% |
| FY2005 Q2 | - | $162.50 | $1.25 | 129.5x | -71% |
| FY2005 Q1 | - | $254.00 | $1.52 | 167.1x | -63% |
| FY2004 Q4 | Dec 31 2004 | $296.00 | $1.44 | 205.6x | -55% |
| FY2004 Q3 | - | $299.00 | $1.04 | 287.5x | -37% |
| FY2004 Q2 | Jun 30 2004 | $337.00 | $1.23 | 274.0x | -40% |
| FY2004 Q1 | Mar 31 2004 | $380.00 | $1.43 | 265.7x | -41% |
| FY2003 Q4 | Dec 31 2003 | $558.00 | $1.67 | 334.1x | -26% |
| FY2003 Q3 | - | $369.00 | $2.04 | 180.9x | -60% |
| FY2002 Q4 | - | $135.00 | $1.92 | 70.3x | -85% |
| FY2002 Q3 | Sep 30 2002 | $95.00 | $0.72 | 131.9x | -71% |
| FY2002 Q2 | Jun 30 2002 | $140.10 | $0.71 | 197.3x | -57% |
| FY2002 Q1 | Mar 31 2002 | $148.00 | $0.58 | 255.2x | -44% |
| FY2001 Q4 | Dec 31 2001 | $152.00 | $0.48 | 316.7x | -30% |
| FY2001 Q3 | Sep 30 2001 | $137.00 | $1.01 | 135.6x | -70% |
| FY2001 Q2 | Jun 30 2001 | $178.00 | $1.37 | 129.9x | -71% |
| FY2001 Q1 | Mar 31 2001 | $225.00 | $1.85 | 121.6x | -73% |
| FY2000 Q4 | Dec 31 2000 | $225.00 | $2.01 | 111.9x | -75% |
| FY2000 Q3 | Sep 30 2000 | $281.25 | $2.54 | 110.7x | -76% |
| FY2000 Q1 | Mar 31 2000 | $400.00 | $2.14 | 186.9x | -59% |
| FY1999 Q3 | - | $171.90 | $1.65 | 104.2x | -77% |
Average P/E for displayed period: 453.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TRIB — Frequently Asked Questions
Quick answers to the most common questions about buying TRIB stock.
What is TRIB's P/E ratio?
Trinity Biotech plc (TRIB) trailing twelve-month P/E ratio is -0.2x, based on TTM diluted EPS of $-2.01. The 5-year average P/E is 890.9x and the historical range spans 77.6x to 5451.9x.
Is TRIB stock overvalued or undervalued?
TRIB trades at -0.2x P/E, below its 5-year average of 890.9x. At the 0th percentile of its historical range (77.6x–5451.9x), the stock is priced at a discount to its own history.
Is TRIB stock expensive?
No, TRIB is not expensive on a historical basis. The current P/E of -0.2x is below the 5-year average of 890.9x and sits at the 0th percentile of its valuation range.
What is TRIB's historical P/E range?
Over the past 5 years, TRIB's P/E ratio has ranged from 77.6x to 5451.9x, with a median of 523.8x and an average of 890.9x. The current P/E of -0.2x places the stock at the 0th percentile of this range. Full historical data spans 1999–2021.
How does TRIB's P/E compare to the S&P 500?
TRIB trades at -0.2x P/E versus the S&P 500 median of 25.3x. The 101% discount to the market suggests lower growth expectations or perceived higher risk.
How does TRIB's valuation compare to Healthcare peers?
Trinity Biotech plc P/E of -0.2x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TRIB's PEG ratio?
TRIB PEG ratio is N/A, based on a P/E of -0.2x and EPS growth of -13.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TRIB's earnings yield?
TRIB earnings yield is N/A, the inverse of its -0.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.